Can I read Results of the Accord 12/0405 Prodige2 Randomized Trial are in Favor of Benefit of Radiation Dose Intensification in the Neoadjuvant Treatment of T3–4 M0 Rectal Cancer on EtoBox?

Results of the Accord 12/0405 Prodige2 Randomized Trial are in Favor of Benefit of Radiation Dose Intensification in the Neoadjuvant Treatment of T3–4 M0 Rectal Cancer by J. Gerard; P. Rouanet; S. Gourgou-Bourgade; I. Martel-Laffay; C. Hennequin; P. Etienne; V. Vendrely; D. Peiffert; K. Benezery; C. Montoto-Grillot is a Medicine article available to read on EtoBox.

What is Results of the Accord 12/0405 Prodige2 Randomized Trial are in Favor of Benefit of Radiation Dose Intensification in the Neoadjuvant Treatment of T3–4 M0 Rectal Cancer about?

Purpose/Objective(s): Following the results of randomized trials (FFCD 9203, RTOG 0012) showing in T3-4 M0 rectal a better local control with neoadjuvant chemoradiation (CT-RT), the ACCORD 12/0405 Prodige2 was launched to define an optimum regimen. Materials/Methods: Inclusion was rectal adenocarcinoma accessible to digital rectal examination T3 or resectable T4 Nx M0 below 80 years. Treatment A: concurrent RT 45 Gy/25f/5 weeks (w) + capecitabine (800 mg/m 2 /b.i.d.). Treatment B: concurrent RT 50 Gy/25f/5 weeks + capecitabine (800 mg/m 2 /b.i.d./5/7 days) + oxaliplatin 50 mg/m 2 /week. Resection with total mesorectum excision was scheduled 6 weeks after the end of CT-RT. Adjuvant chemotherapy was optional. A total of 590 patients were needed to show an increase in the pathologic complete response (Dworak) rate from 11% (arm A) to 20% (arm B). Circumferential positive rectal margin (CRM R1) was defined as the presence of residual cancer cells within 0-1 mm from the perirectal surface. Evaluation of sexual and bowel function was made with a specific questionnaire. Results: This trial closed in July 2008 after randomization of 598 patients since November 2005. Patients' characteristi

Who reads Results of the Accord 12/0405 Prodige2 Randomized Trial are in Favor of Benefit of Radiation Dose Intensification in the Neoadjuvant Treatment of T3–4 M0 Rectal Cancer?

Author

J. Gerard; P. Rouanet; S. Gourgou-Bourgade; I. Martel-Laffay; C. Hennequin; P. Etienne; V. Vendrely; D. Peiffert; K. Benezery; C. Montoto-Grillot

Publisher

Elsevier Science; Elsevier ; Elsevier BV (ISSN 0360-3016)

Published

2009

Language

EN

Field

Medicine (Health Sciences)